BICO Group AB (publ) (CLLKF) Q2 2025 Earnings Call Transcript

BICO Group reported a challenging Q2 2025, with organic sales down 17% and adjusted EBIT at negative SEK 49 million, primarily driven by a significant 58% organic decline and -116% EBITDA margin in its Lab Automation segment. This underperformance stemmed from project delays and a SEK 40 million negative re-estimation of project hours at Biosero, prompting BICO to implement operational and leadership changes. While Life Science Solutions delivered flat organic growth amidst mixed market conditions, the quarter's key strategic move was the divestment of MatTek and Visikol for $80 million, which substantially strengthened BICO's balance sheet to a pro forma net cash position of SEK 270 million, enabling debt reduction and a sharpened focus on its core Lab Automation and Life Science Solutions businesses.

Analysis

BICO Group's second-quarter 2025 results present a stark contrast between severe operational challenges and a significantly improved strategic and financial position. Financially, the quarter was weak, with group sales falling to SEK 324 million, a 17% organic decline, and the adjusted EBIT turning to a loss of SEK 49 million. The primary driver of this underperformance was the Lab Automation business area (Biosero), which saw revenue collapse by 58% organically to SEK 48 million, resulting in an adjusted EBITDA margin of negative 116%. This was directly attributed to project delays and a substantial negative revenue re-estimation of SEK 40 million due to miscalculated project hours, revealing that high demand has outpaced the division's organizational capacity and project management capabilities. In response, management is executing a comprehensive turnaround plan involving leadership changes, investments in operational resources, and implementing stricter project and contract management. In contrast, the larger Life Science Solutions segment remained stable with flat organic growth, in line with peers, supported by healthy growth in the SCIENION diagnostics business which offset softness in the academia-focused instrument segment impacted by US macro headwinds. The quarter's defining event was the divestment of MatTek and Visikol for USD 80 million, generating net proceeds of SEK 740 million. This transaction has transformed BICO's balance sheet, creating a pro forma net cash position of approximately SEK 270 million and providing the capital to resolve its outstanding convertible bond, thereby de-risking the company's financial profile and sharpening its strategic focus on the core Lab Automation and Life Science Solutions businesses.

Key Decisions for Investors

• Investors should recognize that the investment thesis for BICO now hinges almost entirely on the successful operational turnaround of the high-potential but troubled Biosero (Lab Automation) division; monitor upcoming quarters for evidence of improved project execution and margin stabilization.
• Factor in continued margin pressure and potential near-term losses in the Lab Automation segment, as management has explicitly stated that necessary investments in operational resources will negatively impact profitability before the full benefits of the turnaround are realized.
• Acknowledge that the balance sheet has been significantly de-risked following the MatTek and Visikol divestment, providing a crucial financial runway to execute the Biosero transformation without immediate liquidity concerns.
• Closely watch the performance of the Life Science Solutions segment, as continued strength in its diagnostics-focused entities like SCIENION could provide a valuable buffer against the ongoing volatility in the Lab Automation business and weakness in the academia end-market.